Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Stock Short Interest Report for October

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 179,643 shares, a growth of 802.7% from the September 30th total of 19,900 shares. Based on an average daily volume of 5,927,980 shares, the short-interest ratio is presently 0.0 days. Currently, 14.1% of the company’s stock are short sold.

Scinai Immunotherapeutics Stock Down 3.4%

Shares of Scinai Immunotherapeutics stock traded down $0.02 during trading on Wednesday, hitting $0.51. 12,991 shares of the stock were exchanged, compared to its average volume of 778,688. The company has a fifty day moving average price of $1.66 and a 200-day moving average price of $4.59. Scinai Immunotherapeutics has a 1-year low of $0.50 and a 1-year high of $15.50.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Scinai Immunotherapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Scinai Immunotherapeutics presently has a consensus rating of “Sell”.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company’s research centers on NanoAb, its proprietary platform of single-domain antibodies designed to target disease-related proteins and potentially support localized treatment with reduced systemic exposure.

Scinai’s lead development program is SCNI-153, a NanoAb-based candidate targeting interleukin-17 (IL-17) for the treatment of plaque psoriasis.